The Chemours Company (CC) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow The Chemours Company ( CC ) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDT Company Participants Brandon Ontjes - Vice President of Investor Relations Denise Dignam - President, CEO & Director Shane Hostetter - Senior VP & CFO Conference Call Participants Peter Osterland - Truist Securities, Inc., Research Division Patrick Fischer - Goldman Sachs Group, Inc., Research Division John Ezekiel Roberts - Mizuho Securities USA LLC, Research Division Hassan Ahmed - Alembic Global Advisors Joshua Spector - UBS Investment Bank, Research Division Arun Viswanathan - RBC Capital Markets, Research Division Caleb Boehnlein - BMO Capital Markets Equity Research Vincent Andrews - Morgan Stanley, Research Division Aaron Rosenthal - JPMorgan Chase & Co, Research Division Presentation Operator Good morning. My name is Therese, and I will be your conference operator today. I would like to welcome everyone to The Chemours Company's Second Quarter 2026 Results Conference Call. [Operator Instructions] I would like to remind everyone that this conference call is being recorded. I would now like to hand the conference call over to Brandon Ontjes, Vice President and Head of Strategy and Investor Relations for Chemours. You may begin. Brandon Ontjes Vice President of Investor Relations Good morning, everybody. Welcome to the Chemours Company's Second Quarter 2026 Earnings Conference Call. I'm joined today by Denise Dignam, Chemours' President and Chief Executive Officer; and our Senior Vice President and Chief Financial Officer, Shane Hostetter. Before we start, I would like to remind you that comments made on this call as well as in the supplemental information provided on our website contain forward-looking statements that involve risks and uncertainties as described in Chemours' SEC filings. These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ, and Chemours undertakes no duty to update any forward-looking